Prognostic Factors in Oligodendrogliomas: a Clinical Study of Twenty-Five Consecutive Patients |
Atalay, Tugay
(Department of Neurosurgery, School of Medicine, Bozok University)
Ak, Hakan (Department of Neurosurgery, School of Medicine, Bozok University) Celik, Bahattin (Department of Neurosurgery, School of Medicine, Harran University) Gulsen, Ismail (Department of Neurosurgery, School of Medicine, Yuzuncu Yil University) Seckin, Hakan (Department of Neurosurgery, Lokman Hekim Private Hospital) Tanik, Nermin (Department of Neurology, School of Medicine, Bozok University) Albayrak, Sedat Baki (Department of Neurosurgery, School of Medicine, Suleyman Demirel University) Bavbek, Murad (Department of Neurosurgery, School of Medicine, Yildirim Beyazit University) |
1 | Ahmed N, Bhurgri Y, Sadiq S, et al (2007). Pediatric brain tumours at a tertiary care hospital in Karachi. Asian Pac J Cancer Prev, 8, 399-404. |
2 | Allam A, Radwi A, El Weshi A, et al (2000). Oligodendroglioma: an analysis of prognostic factors and treatment results. Am J Clin Oncol, 23, 170-5. DOI |
3 | Cairncross G, Macdonald D, Ludwin S, et al (1994). Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 12, 2013-21. |
4 | Coleman KE, Brat DJ, Cotsonis GA, et al (2006). Proliferation (MIB-1 expression) in oligodendrogliomas: assessment of quantitative methods and prognostic significance. Appl Immunohistochem Mol Morphol, 14, 109-14. DOI |
5 | Coons SW, Pearl DK (1998). Mitosis identification in diffuse gliomas: implications for tumor grading. Cancer, 82, 1550-5. DOI |
6 | Engelhard HH, Stelea A, Mundt A (2003). Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol, 60, 443-56. DOI |
7 | Fortin D, Cairncross GJ, Hammond RR (1999). Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery, 45, 1279-91. DOI |
8 | Gheytanchi E, Mehrazma M, Madjd Z (2014). Expression of Ki-67, p53 and VEGF in pediatric neuroblastoma. Asian Pac J Cancer Prev, 15, 3065-70. DOI ScienceOn |
9 | Haroon S, Hashmi AA, Khurshid A, et al (2013). Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients. Asian Pac J Cancer Prev, 14, 4353-8. DOI |
10 | Heegaard S, Sommer HM, Broholm H, et al (1995). Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer, 76, 1809-13. DOI |
11 | Heesters MA, Koudstaal J, Go KG, et al (1999). Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value. J Neurooncol, 44, 255-66. DOI |
12 | Kayaselcuk F, Zorludemir S, Gumurduhu D, et al (2002). PCNA and Ki-67 in central nervous system tumors: correlation with the histological type and grade. J Neurooncol, 57, 115-21. DOI |
13 | Louis DN, Ohgaki H, Wiestler OD, et al (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 114, 97-109. DOI |
14 | Miller CR, Dunham CP, Scheithauer BW, et al (2006). Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol, 24, 5419-26. DOI |
15 | Reis-Filho JS, Faoro LN, Carrilho C, et al (2000). Evaluation of cell proliferation, epidermal growth factor receptor, and bcl-2 immunoexpression as prognostic factors for patients with World Health Organization grade 2 oligodendroglioma. Cancer, 88, 862-9. DOI |
16 | Ocal I, Avci A, Cakalagaoglu F, et al (2014). Lack of correlations among histopathological parameters, Ki-67 proliferation index and prognosis in pheochromocytoma patients. Asian Pac J Cancer Prev, 15, 1751-5. DOI |
17 | Olson JD, Riedel E, DeAngelis LM (2000). Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurol, 54, 1442-8. DOI |
18 | Quon H, Hasbini A, Cougnard J, et al (2010). Assessment of tumor angiogenesis as a prognostic factor of survival in patients with oligodendroglioma. J Neurooncol, 96, 277-85. DOI |
19 | Scerrati M, Roselli R, Iacoangeli M, et al (1996). Prognostic factors in low grade (WHO grade II) gliomas of the cerebral hemispheres: the role of surgery. J Neurol Neurosurg Psychiatry, 61, 291-6. DOI |
20 | Schiffer D, Dutto A, Cavalla P, et al (1997). Prognostic factors in oligodendroglioma. Can J Neurol Sci, 24, 313-9. DOI |
21 | Shaw EG, Scheithauer BW, O'Fallon JR, et al (1992). Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg, 76, 428-34. DOI |
22 | Vaquero J, Zurita M, Coca S, et al (2000). Prognostic significance of clinical and angiogenesis-related factors in low-grade oligodendrogliomas. Surg Neurol, 54, 229-34. DOI |
23 | Weidner N, Carroll PR, Flax J, et al (1993). Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol, 143, 401-9. |
24 | Zahir ST, Vakili M, Navabii H, et al (2014). Clinicopathological findings and five year survival rates for patients with central nervous system tumors in Yazd, Iran. Asian Pac J Cancer Prev, 15, 10319-23. |
25 | Wharton SB, Hibberd S, Eward KL, et al (2004). DNA replication licensing and cell cycle kinetics of oligodendroglial tumours. Br J Cancer, 91, 262-9. |
26 | Yates JW, Chalmer B, McKegney FP (1980). Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer, 45, 2220-4. DOI |